ASCO

June 8, 2022

American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022

Year

2022

Target

RVU120 (CDK8/CDK19), PIM/FLT3

Assets in this page

Download assets

  • pdf file

    Phase 1/2 study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in patients with IDH1/2-mutated acute myeloid leukemia: the DIAMOND-01 trial

    Download
  • pdf file

    Phase I/II trial of RVU120 (SEL120), a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors

    Download